SG Americas Securities LLC Sells 117,571 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

SG Americas Securities LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 74.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,350 shares of the biotechnology company's stock after selling 117,571 shares during the period. SG Americas Securities LLC's holdings in BioCryst Pharmaceuticals were worth $311,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,322 shares during the last quarter. Quantinno Capital Management LP bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth $82,000. SkyView Investment Advisors LLC increased its holdings in BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 3,000 shares in the last quarter. nVerses Capital LLC increased its stake in shares of BioCryst Pharmaceuticals by 52.0% in the third quarter. nVerses Capital LLC now owns 15,500 shares of the biotechnology company's stock valued at $118,000 after buying an additional 5,300 shares during the period. Finally, Captrust Financial Advisors boosted its position in shares of BioCryst Pharmaceuticals by 19.4% during the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company's stock valued at $124,000 after purchasing an additional 2,644 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX traded down $0.01 during mid-day trading on Friday, reaching $8.72. 2,340,286 shares of the company's stock traded hands, compared to its average volume of 2,553,611. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.00. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -14.29 and a beta of 1.75. The company has a 50 day moving average price of $7.72 and a 200-day moving average price of $7.72.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Evercore ISI raised their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Barclays raised their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Needham & Company LLC increased their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $15.50.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.